Latest Breaking News On - Restated july - Page 1 : comparemela.com

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable s

United statesSan diegoBristol myers squibbEric pomaAmerican association for cancer researchMolecular templates incChief executiveChief scientific officerComplete responseRestated julyNasdaq capital marketAmerican associationCancer researchAnnual meetingSecond closingShiga like toxin